Red Arrow Therapeutics closes $4.5M Seed Extension funding to advance pH-sensing nanomedicine drug delivery technologies
Red Arrow Therapeutics closes $4.5M Seed Extension funding to advance pH-sensing nanomedicine drug delivery technologies
04/23/24, 7:21 AM
Location
cambridgeMoney raised
$4.5 million
Industry
therapeutics
biotechnology
health care
Round Type
seed
Investors
Osaka University Venture Capital Co., Ltd., Keio Innovation Initiative, Inc., The University Of Tokyo Edge Capital Partners Co., Ltd., Beyond Next Ventures Inc.
Red Arrow Therapeutics Inc., a developer of pH-sensing nanomedicine drug delivery technologies, closed a $4.5M Seed Extension round. The funding will be used to obtain key preclinical data on safety and efficacy of their lead compound, IL-12-loaded nanopolymeric micelles, and enable manufacturing initiation in collaboration with external partners.
Company Info
Location
cambridge, massachusetts, united states
Additional Info
Red Arrow Therapeutics, Inc. is a biotechnology company focusing on developing new technologies that can turn "cold" tumors into inflamed "hot" tumors. Red Arrow Therapeutics' lead product candidate, RA-001, a pH-activated polymer micelle loaded with IL-12, is designed to release fully active IL-12 upon sensing intratumoral pH to safely potentiate immunotherapy.
In the current pre-clinical data, RA-001 exhibits strong anti-tumor immunity in various tumor models. Furthermore, RA-001 shows high efficacy as monotherapy and in combination with immune checkpoint inhibitors.